Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

NCT00676143 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1100

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.

Conditions

Alzheimer Disease

Interventions

DRUG: bapineuzumab
DRUG: placebo

Sponsor

Pfizer